-
Sichuan Kelun-Biotech to Present Promising Phase II Results for SKB264 in mTNBC at SABCS 2023
•
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), is poised to present updated results from a Phase II study expansion cohort for its antibody-drug conjugate, SKB264, targeting previously treated metastatic triple negative breast cancer (mTNBC) at the upcoming San Antonio…
-
TG ImmunoPharma Secures U.S. FDA IND Approval for Promising mAb TGI-5 Targeting Multiple Cancers
•
TG ImmunoPharma Co., Ltd, based in China, has announced that it has received Investigational New Drug (IND) approval from the U.S. FDA for its proprietary monoclonal antibody (mAb), TGI-5. While the specific target of this molecule remains undisclosed, the company claims it could be a potential global first-in-class treatment. TGI-5…
-
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
•
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of a clinical study for its potential first-in-class PHD inhibitor, ISM5411, targeting inflammatory bowel disease (IBD). ISM5411 is an intestinal-restricted small-molecule inhibitor developed using Insilico’s Pharma.AI platform, featuring a novel molecular framework and a unique binding…
-
Simcere Secures NMPA Approval for Edaravone Sublingual Tablets Targeting Post-Stroke Cognitive Impairment
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has received clinical trial approval from the National Medical Products Administration (NMPA) for its edaravone, borneol sublingual tablets, targeting post-stroke cognitive impairment (PSCI) in patients suffering from acute ischemic stroke (AIS). The edaravone, borneol sublingual tablet is a solid oral formulation designed for…
-
Everest Medicines Reports Positive Phase III Results for Velsipity in Ulcerative Colitis
•
Everest Medicines (HKG: 1952), based in China, has announced positive topline results from a multi-center Phase III clinical trial for Velsipity (etrasimod) in patients with moderate-to-severe active ulcerative colitis (UC). Conducted across various sites in Asia, the trial demonstrated clinically meaningful and statistically significant improvements in the primary endpoint, as…
-
Acotec Secures FDA IDE Approval for AcoArt Litos Paclitaxel-Coated Balloon Catheter
•
Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received Investigational Device Exemption (IDE) approval from the U.S. FDA for its AcoArt Litos paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This IDE approval enables Acotec to commence clinical trials for the device, pending Institutional Review Board (IRB) clearance. The…
-
Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital
•
Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing an $8 million seed financing round led by Chengwei Capital. The company has appointed Dr. Kerry Blanchard as co-founder and CEO, following his recent departure from Everest Medicines in August. Perpetual aims to develop an…
-
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
•
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its Takeda Spark incubator program in China. Initially launched in 2021, the incubator program partners with consulting firms PricewaterhouseCoopers and Accenture, tech giant Amazon Web Services, and the investment fund Shanghai Biopharmaceutical Innovative Transformation Fund. Takeda…
